These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36538914)

  • 1. The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
    Masjedi M; Azadikhah S; Zand F; Asmarian N; Sabetian G; Ostovan M; Naderi-Boldaji V
    Acta Haematol; 2023; 146(2):137-143. PubMed ID: 36538914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
    Zohar N; Ellis MH; Dichtwald S; Meyer A; Zohar E; Ifrach N
    Minerva Anestesiol; 2023 May; 89(5):425-433. PubMed ID: 36326777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.
    Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I
    Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactivity of enoxaparin in critically ill patients with normal renal function.
    Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
    Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
    Vahtera A; Vaara S; Pettilä V; Kuitunen A
    Thromb Res; 2016 Mar; 139():10-6. PubMed ID: 26916290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
    Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
    Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
    [No Abstract]   [Full Text] [Related]  

  • 7. Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.
    Benes J; Skulec R; Jobanek J; Cerny V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):204-210. PubMed ID: 34042098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.
    Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G
    Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.
    Vahtera A; Valkonen M; Huhtala H; Pettilä V; Kuitunen A
    Thromb Res; 2017 Oct; 158():71-75. PubMed ID: 28846877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
    Cosmi B; Giannella M; Fornaro G; Cristini F; Patacca A; Castagna A; Mazzaferri F; Testa S; Pan A; Lupi M; Brambilla P; Montineri A; Frattima S; Bignami EG; Salvetti M; De Stefano G; Grandone E; Di Perri G; Rozzini R; Stella A; Romagnoli A; Drago F; Viale P
    BMC Infect Dis; 2023 Oct; 23(1):718. PubMed ID: 37875792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
    de Maat MMR; van Leeuwen HJ; Roovers L; Ahlers SJGM; Lambers J; Hovens MMC
    BMC Pharmacol Toxicol; 2024 Feb; 25(1):16. PubMed ID: 38321487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
    Singer GA; Riggi G; Karcutskie CA; Vaghaiwalla TM; Lieberman HM; Ginzburg E; Namias N; Lineen EB
    J Trauma Acute Care Surg; 2016 Dec; 81(6):1101-1108. PubMed ID: 27488490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
    Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
    JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
    Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
    J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
    Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
    J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients.
    Yim J; Jahan A; Braykov N; Murphy ND; Woods GM
    Pediatr Blood Cancer; 2024 Sep; 71(9):e30942. PubMed ID: 38486078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.